carbamates has been researched along with Cancer, Second Primary in 3 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Encorafenib + binimetinib has a favourable efficacy profile compared to other double combination therapies and a favourable safety profile compared to both double and triple combination therapies." | 2.82 | Comparative efficacy and safety of targeted therapies for BRAF-mutant unresectable or metastatic melanoma: Results from a systematic literature review and a network meta-analysis. ( Berardi, R; Corrie, P; Guidoboni, M; Kolovos, S; Laramée, P; Macabeo, B; Meyer, N; Schlueter, M; Trouiller, JB, 2022) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 3 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Schadendorf, D | 1 |
| Dummer, R | 1 |
| Robert, C | 1 |
| Ribas, A | 1 |
| Sullivan, RJ | 1 |
| Panella, T | 1 |
| McKean, M | 1 |
| Santos, ES | 1 |
| Brill, K | 1 |
| Polli, A | 1 |
| Pietro, AD | 1 |
| Ascierto, PA | 1 |
| Corrie, P | 1 |
| Meyer, N | 1 |
| Berardi, R | 1 |
| Guidoboni, M | 1 |
| Schlueter, M | 1 |
| Kolovos, S | 1 |
| Macabeo, B | 1 |
| Trouiller, JB | 1 |
| Laramée, P | 1 |
| Limmer, A | 1 |
| Swali, R | 1 |
| Robare, S | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A PHASE 3, RANDOMIZED, DOUBLE-BLIND STUDY OF ENCORAFENIB AND BINIMETINIB PLUS PEMBROLIZUMAB VERSUS PLACEBO PLUS PEMBROLIZUMAB IN PARTICIPANTS WITH BRAF V600E/K MUTATION-POSITIVE METASTATIC OR UNRESECTABLE LOCALLY ADVANCED MELANOMA[NCT04657991] | Phase 3 | 624 participants (Anticipated) | Interventional | 2021-01-15 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for carbamates and Cancer, Second Primary
| Article | Year |
|---|---|
STARBOARD: encorafenib + binimetinib + pembrolizumab for first-line metastatic/unresectable
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; C | 2022 |
Comparative efficacy and safety of targeted therapies for BRAF-mutant unresectable or metastatic melanoma: Results from a systematic literature review and a network meta-analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bayes Theorem; Benzimidazoles; Carbamates; Humans; M | 2022 |
1 other study available for carbamates and Cancer, Second Primary
| Article | Year |
|---|---|
Multiple Pigmented Lesions of the Breast Following Ipsilateral Breast Carcinoma.
Topics: Aged; Androstadienes; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzimi | 2020 |